NIKKEI 225
38,299.71 +25.66 (+0.07%) HANG SENG
18,121.43 +358.40 (+2.02%) CRUDE OIL
79.40 +0.40 (+0.51%) GOLD FUTURES
2,330.00 +19.00 (+0.82%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,847.91 -1,910.88 (-4.00%)
GSK Aug 2024 48.000 put
| Previous close | 7.20 |
| Open | 7.20 |
| Bid | 4.60 |
| Ask | 6.50 |
| Strike | 48.00 |
| Expiry date | 2024-08-16 |
| Day's range | 7.20 - 7.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 91 |
BenzingaGSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
Wednesday, GSK Plc (NYSE:GSK) reported first-quarter sales of $9.33 billion (7.4 billion Sterling Pounds), up 10% Y/Y and 13% excluding COVID. Vaccines’ sales increased 16% at constant currency to 2.28 billion Pounds, reflecting U.S. demand for Arexvy and strong market growth for Shingrix in International and European markets. Shingrix sales reached 945 million Pounds, up 18% at constant currency, with Arexvy sales of 182 million Pounds. Specialty Medicine sales increased 17% to 2.5 billion poun
PA Media: MoneyGSK raises profit guidance as vaccine demand grows
Emma Walmsley, chief executive officer of the pharmaceutical firm hailed a ‘strong start to 2024’.
ZacksGSK (GSK) Q1 Earnings and Revenues Surpass Estimates
Glaxo (GSK) delivered earnings and revenue surprises of 15.96% and 3.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
